At Molecular Matrix,

we believe in improving lives

through innovations in science

and technology.

 

Nearly a decade ago, Molecular Matrix developed a breakthrough tissue regeneration technology. This platform technology gave rise to our first clinical product, a bone graft substitute used in orthopedic surgery for real-time bone tissue regeneration.

​

Charles Lee, CEO, CSO, and inventor of the technology, introduces Osteo-P technology, which provides a broad platform for bone engineering. Our technology can be used to repair damaged or missing bone while addressing many of the limitations and side effects seen in the orthopedic reconstruction field. The advancements brought by our technology will yield superior bone regeneration products and procedures for orthopedic, spine, and trauma applications.

​

MMI is on a continuous quest to innovate in the biotechnology and biomedical fields. Our vision is to develop life-enhancing and life-saving treatments that will be available worldwide. Research and development at our headquarters is under way to expand the therapeutic applications of our core technology. Our scientists are optimizing the technology for multiple tissue regeneration applications, both in vivo and in vitro.